Overview

Safety, Tolerability, and Efficacy of PLX-200 in Patients With CLN3

Status:
Not yet recruiting
Trial end date:
2024-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and efficacy of multiple doses of PLX-200 in patients with CLN3 disease.
Phase:
Phase 3
Details
Lead Sponsor:
Polaryx Therapeutics, Inc.
Treatments:
Gemfibrozil